11/12/2025
📢 Ascend Clinical Research is now a Strategic Partner of Cybin Inc. for the EMBRACE Phase 3 Study
We are pleased to announce that Ascend Clinical Research has been named a strategic partner of Cybin for EMBRACE, a multinational Phase 3 clinical study evaluating CYB003 as an adjunctive treatment for Major Depressive Disorder (MDD).
This collaboration marks a significant advancement in our mission to support groundbreaking, evidence-based mental health treatments.
As our CEO Cara Caasi Singh shares:
“This is a pivotal moment in Ascend’s milestones. Together with our Senior Leadership team ( Alexandra Diaz (COO), Dr. David Torku (Medical Director), and Zane Courbay, (VP)), we are committing to facilitate this study with integrity, safety, and excellence.”
Why this partnership matters:
✨ CYB003 is among the most promising psychedelic-derived therapeutic candidates for depression.
✨ Phase 3 marks a major step toward bringing innovative mental health treatments to patients worldwide.
✨ Ascend is proud to contribute our expertise and commitment to scientific excellence to a study that may transform MDD care.
To individuals, clinicians, and community partners interested in our mental health research programs:
đź”— Visit: www.ascendclinical-research.com
📞 Contact us: +44 (0) 7776-955-230
Together with Ascend Clinical Research, we move forward in shaping the future of mental health treatment.